Cleave Therapeutics

About:

Cleave Therapeutics is focused on protein homeostasis and stress pathways in cancer and neurodegeneration.

Website: http://www.cleavetherapeutics.com

Top Investors: New Enterprise Associates, OrbiMed, U.S. Venture Partners, Nextech Invest, 5AM Ventures

Description:

Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer.

Total Funding Amount:

$101M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Francisco, California, United States

Founded Date:

2010-01-01

Contact Email:

info(AT)cleavetherapeutics.com

Founders:

Peter Thompson, Ray Deshaies

Number of Employees:

11-50

Last Funding Date:

2019-08-06

IPO Status:

Private

Industries: